Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up of a prospective multicenter cohort study

Publication: Breast Cancer Research and Treatment 2024

Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W. G. van der Velden, Sabine Siesling, Anja N. H. Timmer‑Bonte, Tineke J. Smilde, Alex L. T. Imholz, Charlotte F. J. M. Blanken‑Peeters, Bart de Valk, Suzan Vrijaldenhoven, Willem B. Lastdrager, Annebeth W. Haringhuizen, Jarmo C. B. Hunting, Sjoerd Hovenga, Peter Nieboer, Hanneke M. Zuetenhorst, Geert W. M. Tetteroo, Carolien H. Smorenburg, Marissa C. van Maaren, Thijs van Dalen

Background: A previous prospective multicenter study revealed the change of the oncologists’ chemotherapy advice due to the 70-Gene signature (GS) test result in half of the estrogen receptor-positive (ER+) invasive early-stage breast cancer patients with disputable chemotherapy indication. This resulted in less patients receiving chemotherapy. This study aims to complement these results by the 7-year oncological outcomes according to the 70-GS test result and the oncologists’ pre-test advice.